绿叶制药抗抑郁1类创新药若欣林®在中国澳门获批上市

参考文献：

1.Huang, Z., Wu, J., Guan, Y. et al. PET/CT study of dopamine transporter (DAT) binding with the triple reuptake inhibitor toludesvenlafaxine in rats and humans. Eur J Nucl Med Mol Imaging 51, 2638–2648 (2024). https://doi.org/10.1007/s00259-024-06700-2

2.Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov;163(11):1905-17

3.Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010 Jan;40(1):41-50

4.肖乐, 丰雷, 朱雪泉, 等. 中国抑郁症患者急性期治疗后残留症状的现况调查 [J] . 中华精神科杂志,2017,50 (03): 175-181

5.Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998 Sep;50(2-3):97-108

6.Carvalho AF, Sharma MS, Brunoni AR, et al. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother Psychosom. 2016;85(5):270-88

7.Zhu Y, Wu Z, Sie O, et al. Causes of drug discontinuation in patients with major depressive disorder in China. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jan 10;96:109755

文章来源：绿叶常青学苑 微信公众号